4//SEC Filing
Baker Brian Lee 4
Accession 0001209191-21-002840
CIK 0001595893other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 9:08 PM ET
Size
29.3 KB
Accession
0001209191-21-002840
Insider Transaction Report
Form 4
Baker Brian Lee
VP of Finance and Admin.
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-01-07−10,689→ 30,356 totalExercise: $7.43Exp: 2029-02-19→ Common Stock (10,689 underlying) - Exercise/Conversion
Common Stock
2021-01-07$5.12/sh+4,545$23,270→ 21,557 total - Sale
Common Stock
2021-01-07$120.16/sh−900$108,144→ 28,546 total - Sale
Common Stock
2021-01-07$121.57/sh−5,200$632,164→ 23,346 total - Exercise/Conversion
Stock Option (right to buy)
2021-01-07−11,905→ 14,069 totalExercise: $2.19Exp: 2027-08-08→ Common Stock (11,905 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-01-07−1,299→ 1,298 totalExercise: $3.20Exp: 2028-03-08→ Common Stock (1,299 underlying) - Exercise/Conversion
Common Stock
2021-01-07$7.43/sh+10,689$79,419→ 32,246 total - Sale
Common Stock
2021-01-07$123.02/sh−513$63,109→ 1,008 total - Exercise/Conversion
Common Stock
2021-01-07$2.19/sh+11,905$26,072→ 15,713 total - Exercise/Conversion
Common Stock
2021-01-07$3.20/sh+1,299$4,157→ 17,012 total - Sale
Common Stock
2021-01-07$122.65/sh−2,800$343,420→ 29,446 total - Sale
Common Stock
2021-01-07$122.44/sh−21,825$2,672,253→ 1,521 total - Exercise/Conversion
Stock Option (right to buy)
2021-01-07−4,545→ 11,039 totalExercise: $5.12Exp: 2028-11-05→ Common Stock (4,545 underlying)
Footnotes (11)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
- [F10]1/48th of the shares vest monthly following November 6, 2018.
- [F11]25% of the shares vest on February 12, 2020 and 1/48th of the shares vest monthly thereafter over the next three years.
- [F2]The Reporting Person acquired 365 shares on June 12, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 427 shares on December 10, 2020 pursuant the ESPP.
- [F3]The weighted average sale price for the transaction reported was $122.65, and the range of prices were between $122.50 and $123.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $120.16, and the range of prices were between $119.90 and $120.68. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $121.57, and the range of prices were between $120.96 and $121.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The weighted average sale price for the transaction reported was $122.44, and the range of prices were between $121.97 and $122.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F7]The weighted average sale price for the transaction reported was $123.02, and the range of prices were between $122.98 and $123.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F8]One-fourth of the option vested on July 6, 2018. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested.
- [F9]Vests in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018.
Documents
Issuer
Turning Point Therapeutics, Inc.
CIK 0001595893
Entity typeother
Related Parties
1- filerCIK 0001772399
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 9:08 PM ET
- Size
- 29.3 KB